I’m not the one designing the smile. I’m actually building the foundation. What we’re seeing with GLP-1 patients is a pretty meaningful shift in who’s walking through the door and what they’re focused on. Over the past few years -- and more significantly, the last 12 to 18 months -- more patients on medications like Ozempic, Wegovy, and Mounjaro (tirzepatide) are showing up having lost significant weight, and now, they’re prioritizing their oral health. Many have delayed care for years. Now they feel better, look better, and they’re ready to fix what had been neglected.
That means more extractions of hopeless teeth, more bone grafting, and more implant consultations for partial and full-mouth rehabilitation. It’s a good thing that more people are focused on health and wellness, and the connection between oral and systemic health seems to be more universally accepted and understood, but it comes with nuances we didn’t have to think about just a few years ago.
Clinical considerations that matter to us
Dr. Jason M. Auerbach.
Rapid weight loss changes the soft-tissue envelope. We’re seeing less facial volume, more skin laxity, and a different perioral profile. From a surgical standpoint, those changes affect how patients perceive outcomes, especially in the anterior maxilla and aesthetic zone. The bone can be perfect, the implant can be perfectly placed, but if the soft-tissue support and lip dynamics are changing, expectations need to be managed early.
We’re also seeing more interest in procedures beyond dentoalveolar surgery, including patients asking about jaw repositioning and elective aesthetic procedures. Whether that translates to orthognathic surgery or adjunctive procedures like submental liposuction depends on the case, but the awareness is clearly higher. They’re paying attention to their faces in a way they weren’t before.
Anesthesia and NPO: The biggest issue for oral surgeons
The biggest immediate impact for us is anesthesia. GLP-1 medications delay gastric emptying. That changes the risk profile for office-based sedation.
Historically, nil per os (NPO) guidelines were straightforward. Now, they’re not. Patients don’t always volunteer that they’re on a GLP-1, and even when they do, they may not understand why it matters.
We’ve had to get very explicit: “If you’re taking a medication like Ozempic or Wegovy, you need to tell us, and we may modify timing or even defer sedation.” The concern is retained gastric contents and aspiration risk under anesthesia. That’s real, and it’s a growing concern. So, our pre-op screening is tight, our conversations are clear, and our threshold to adjust or postpone is lower. Patient safety dictates that.
Treatment sequencing and timing
From a surgical sequencing standpoint, I’m less concerned about waiting for “facial stability” than I would be in a purely cosmetic workflow, but it definitely still matters.
If a patient is midtrajectory with significant ongoing weight loss, I’m thoughtful about staging. Extract, graft, preserve bone. Create options. Let things declare themselves before committing to definitive implant positioning in highly aesthetic areas if there’s any question about tissue dynamics, but we don’t overdelay care that’s clearly indicated. Infection, pain, and nonrestorable teeth always get addressed. The key is separating urgency from optimization.
The patient conversation
These patients are motivated, which is advantageous, but they’re also moving fast. They’ve seen rapid change and want the rest to catch up, so when they understand our role as building a foundation for the final result, they get it.
What’s changed, and what’s next
What I wish we all appreciated earlier is that this isn’t just a weight loss story. For surgeons and general dentists: Ask better questions, document GLP-1 use clearly, and respect the anesthesia implications. That’s the nonnegotiable.
Where research needs to go: clearer guidance on perioperative management of GLP-1 patients in office-based anesthesia settings and better data on how rapid weight loss affects bone metabolism and healing around grafts and implants. We’re making good clinical decisions, but we need stronger evidence behind them.
Dr. Jason M. Auerbach is a full-scope oral and maxillofacial surgeon, certified by both the American Board of Oral and Maxillofacial Surgery and the National Dental Board of Anesthesiology. Auerbach’s areas of practice emphasis include dental implants, bone grafting, and wisdom teeth extraction. He founded Riverside Oral Surgery in 2007 and in so doing, realized his vision of providing the optimal patient experience through clinical excellence, compassionate care, and close attention to every detail.
The comments and observations expressed herein do not necessarily reflect the opinions of DrBicuspid.com, nor should they be construed as an endorsement or admonishment of any particular idea, vendor, or organization.
